Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection?

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Tulenko, Thomas N ^a   Laury Kleintop, Lisa ^a   Walter, Mary F ^a   Preston Mason, R ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Amlodipine; Antioxidants; Arterial smooth muscle; Cell proliferation; Gene expression; Membranes; Norvasc; Phospholipids; Rabbits; Vascular disease

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ISRADIPINE; NIMODIPINE; PHOSPHOLIPID; PLACEBO; VERAPAMIL;

ANIMAL CELL; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; VASCULAR SMOOTH MUSCLE;

EID: 0031593076     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00242-8     Document Type: Conference Paper

References (61)

1. Kannel W.B., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 90:1979;825-836.
2. Kannel W.B., Neaton J.D., Wentworth D. Overall coronary heart disease mortality rate in relation to major risk factors in 325 348 men screened for the MRFIT. Am Heart J. 112:1986;825-836.
3. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-37.
4. Kannel W.B. High density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 52:1983;9B-13B.
5. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenecity. N Engl J Med. 320:1989;915-924.
6. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1995;330:1029-1035.
7. Walldius G., Erikson U., Olsson A.G.et al. The effect of probucol on femoral atherosclerosis: the Probucol quantitative regression Swedish trial (PQRST). Am J Cardiol. 74:1994;875-883.
8. Lenfant C, NIH ALERT on β-carotene study findings (CARET). Bethesda, MD: National Institutes of Health, January 18, 1995; Embargoed Release.
9. Bloch K. Sterol structure and membrane function. Crit Rev Biochem. 14:1983;47-92.
10. Yeagle P.L. Cholesterol and the cell membrane. Biochim Biophys Acta. 822:1985;267-287.
11. Tulenko TN, Lopatofsky D, Cox RH, Mason RP, Cholesterol in cell plasma membranes. In: Encyclopedia of aging. Academic Press, 1996:279-288.
12. Chen M., Mason R.P., Tulenko T.N. Atherosclerosis alters composition, structure and function of arterial smooth muscle plasma membranes. Biochim Biophys Acta. 1272:1995;101-112.
13. Gleason M.M., Medow M.S., Tulenko T.N. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 69:1991;216-227.
14. 2+ uptake following cholesterol enrichment of endothelial cells. J Vasc Res. 33:1996;61.
15. 3) on atherosclerotic arterial smooth muscle cells. FASEB J. 7:1993;792.
16. Tulenko TN, Mason RP, Chen M, Tasaki H, Rock DE, Stepp DW. Atherogenic activity caused by excess membrane cholesterol in arterial smooth muscle: Role of calcium channels. In: Paoletti R, Godfraind T, Vanhoutte PM, editors. Calcium antagonists - pharmacology and clinical research. Boston: Kluwer, 1993:107-115.
17. Chang M., Sasahara M., Chait A., Raines E., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Arterioscl Thromb Vasc Biol. 15:1995;1631-1640.
18. Raines E., Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 69:1993;S30-S37.
19. Ross R. Cell biology of atherosclerosis. Ann Rev Physiol. 57:1995;791-804.
20. Rabini R.A., Polenta M., Staffolani R.et al. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp Mol Pathol. 59:1993;51-57.
21. +-ATPase and bile flow by estrogen: Effects on liver surface membrane lipid structure and function. Proc Natl Acad Sci. 75:1978;4130-4134.
22. Shattil S.J., Cooper R.A. Membrane microviscosity and human platelet function. Biochemistry. 15:1976;4832-4837.
23. +-ATPase activity. Am J Physiol. 254:1988;G687-G694.
24. Medow M., Segal S. Age-related changes in fluidity of rat renal brushborder membrane vesicles. Biochem Biophys Res Comm. 142:1987;849-856.
25. Nabekura T., Takano M., Inui K. Cholesterol modulates organic cation transport activity and lipid fluidity in rat renal brush-border membranes. Biochim Biophys Acta. 1283:1996;232-236.
26. Tulenko T.N., Chen M., Stepp D., Laury-Kleintop L., Moisey D.M., Mason R.P. The actions of the charged dihydropyridine amlodipine (Norvasc) in a cell culture model of dietary atherosclerosis. J Cardiovasc Pharmacol. 26(Suppl A):1995;S11-S17.
27. 2+ movements and vasoconstriction in atherosclerotic aorta. Arterioscl Thromb. 14:1994;1854-1859.
28. Bialecki R.A., Tulenko T.N. Excess membrane cholesterol alters calcium channel activity in smooth muscle of rabbit carotid arteries. Am J Physiol. 257:1989;H170-H178.
29. + channels in arterial smooth muscle. FASEB J. 5:1991;A532.
30. Broderick R., Bialecki R., Tulenko T.N. Cholesterol-induced changes in arterial sensitivity to adrenergic stimulation. Am J Physiol. 257:1989;H170-H178.
31. Jackson C.L., Bush R.C., Bowyer D.E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis. 80:1989;17-26.
32. Henry P.D. Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis. 10:1990;963-965.
33. Parmley WW. Calcium antagonists in the prevention of atherosclerosis. In: Messerli FH, editor. Cardiovascular drug therapy. Philadelphia: WB Saunders, 1996:901-907.
34. Overturf M. Are calcium ion antagonists effective anti-atherogenic agents? Arteriosclerosis. 10:1990;961-962.
35. Nayler W.G. Experimental models to study the prevention of atherosclerosis by calcium antagonists. J Cardiovasc Pharmacol. 26(Suppl A):1995;S18-S24.
36. Nayler W.G. The antiatherogenic effects of amlodipine: Promise of preclinical data. J Hum Hypertens. 6(Suppl 1):1992;S19-23.
37. Kramsch D.M. Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherogenic agent. J Hum Hypertens. 9(Suppl 1):1995;S3-S9.
38. Tulenko TN, Brown J, Laury-Kleintop LL, Kahn MB, Walter MF, Mason RP. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. J Cardiovasc Pharmacol 1997 (in press).
39. Weisbrod R.M., Griswold M.C., Du Y., Bolotina V.M., Cohen R.A. Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxide. Arterioscler Thromb. 17:1997;394-402.
40. Phair R.D. Cellular calcium and atherosclerosis: A brief review. Cell Calcium. 9:1988;275-284.
41. Tulenko T.N., Chen M., Stepp D., Mason R.P., Laury-Kleintop L. Modulation of membrane and functional parameters in arterial smooth muscle cells in dietary atherosclerosis by cholesterol. J Vasc Res. 33:1996;101.
42. Stein O., Halpern G., Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis. 7:1987;585-592.
43. Etingon O.R., Hajjar D.P. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiathergenic effect. J Clin Invest. 75:1985;1554-1558.
44. Daugherty A., Rateri D.L., Schonfeld G., Sobel B.E. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol. 91:1987;113-118.
45. ++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. II. Characterization of intracellular morphologic changes. Arteriosclerosis. 8:1988;57-67.
46. ++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. I. Characterization of cellular lipid metabolism. Arteriosclerosis. 8:1988;46-56.
47. Nilsson J., Sjolund M., Palmberg L., Von Euler A.M., Jonzon B., Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis. 58:1985;109-122.
48. 2+ channels. Kidney Int. 49:1996;868-879.
49. Dol F., Schaeffer P., Lamarche I., Mares A., Chatelain P., Herbert J. Effect of SR 33805 on arterial smooth muscle cell proliferation and neointima formation following vascular injury. Eur J Pharmacol. 280:1995;135-142.
50. Zhu D.L., Herembert T., Caruelle D., Caruelle J.P., Marche P. Involvement of calcium channels in fibroblast growth factor-induced activation of arterial cells in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 23:1994;395-400.
51. Herembert T., Zhu D.L., Marche P. Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats. Br J Hypertens. 114:1995;1703-1709.
52. Mason R.P., Campbell S.F., Wang S., Herbette L.G. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol. 36:1989;634-640.
53. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol. 41:1992;315-321.
54. Mason R.P. Membrane interactions of calcium channel antagonists modulated by cholesterol: implications for drug activity. Biochem Pharm. 45:1993;2173-2183.
55. 2+-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci. 88:1991;9041-9045.
56. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci. 93:1996;5478-5482.
57. Ko Y., Totzke G., Graack G.et al. Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens. 11:1993;1171-1178.
58. Roth M., Keul R., Emmons L.R., Horl W.H., Block L.H. Manidipine regulates the transcription of cytokine genes. Proc Nat Acad Sci. 89:1992;4071-4075.
59. Feron O., Salomone S., Godfraind T. Blood pressure-independent inhibition by lacidipine of endothelin-1-related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharm. 26:1995;S459-S461.
60. Packer M., O'Conner C.M., Ghali J.K.et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
61. Packer M., Kessler P.D., Lee W.H. Calcium channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation. 75(Suppl V):1987;V56-V64.